scholarly journals The Difference Of Visual Acuity And Macular Thickness Post Bevacizumab Therapy In Secondary Macular Edema Retinal Vein Occlusion

2018 ◽  
Vol 4 (2) ◽  
pp. 110
Author(s):  
Citra Rahmadani ◽  
Nur Khoma Fatmawati ◽  
Rahmat Bakhtiar
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Secondary Data ◽  
Macular Thickness ◽  
Vein Occlusion ◽  
Before And After ◽  
Quasi Experimental ◽  
The Mean ◽  
The Difference

Retinal vein occlusion is the second most common cause of blindness in retinal vascular disease after diabetic retinopathy and may lead to complications of macular edema. Bevacizumab is an influential treatment as an anti vascular endothelial growth factor (VEGF). This study aims to determine the difference of visual acuity and macular thickness before and after treatment of Bevacizumab. This is a quasi experimental study in patients with secondary macular edema retinal vein occlusion who meets the inclusion criteria. Visual acuity and macular thickness were evaluated after one month of treatment. This study was conducted for two months since May-June 2017 by collecting secondary data from medical record at SMEC Samarinda from January 2016 – June 2017. Data were analyzed using Wilcoxon. Sixteen eyes from 16 patients were diagnosed with macular edema secondary retinal vein occlusion given bevacizumab treatment. The mean visual acuity before therapy was 1.106 LogMAR ± 0.509 and increased to 0.889 logMAR ± 0.608 (p = 0.116) after treatment while the mean macular thickness before therapy was 504.06 μm ± 301.273 and decreased to 348.81 μm ± 181.17 (p = 0.017) after treatment. There was a significant effect on the decrease in macular thickness but no significant effect on visual acuity improvement in patients with macular edema secondary retinal vein occlusion at SMEC Samarinda.  Keywords: Retinal vein occlusion, macular edema, bevacizumab

scholarly journals Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Massimo Nicolò ◽  
Monica Bonetto ◽  
Raffaella Rosa ◽  
Donatella Musetti ◽  
Maria Musolino ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Real Life ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
Web Platform

Aim.Real-lifeevaluation in the management of patients affected by macular edema secondary to retinal vein occlusion.Material and Methods. A retrospective, observational study using theI-Macula Webplatform.Results. Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p=0.0235) and central macular thickness (p<0.0001). The mean change in visual acuity was 8.9 letters. Twenty-seven eyes underwent DEX implant (n=62; mean: 2.29) only. Of these, 8, 4, 14, and 1 eyes underwent 1, 2, 3, and 4 DEX implants, respectively. The remaining 10 eyes were also injected with ranibizumab (n=49; mean: 4.9). At 12 months, 12 eyes (32.5%) presented a dry macula, whereas the remaining 25 eyes (67.5%) still had macular edema. Mean interval between the first and second treatment (T1) and between the second and third treatment (T2) were 5.15 and (T2) 3.7 months, respectively. Where only DEX implants were received, T1 and T2 was 5.1 and 4.9 months, respectively.Conclusions. This study confirms that DEX implants and/or anti-VEGF drugs improve visual acuity and central macular thickness in patients affected by RVO.

Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion

2018 ◽  
Vol 28 (6) ◽  
pp. 690-696 ◽  
Author(s):  
Yelda Buyru Özkurt ◽  
Sezen Akkaya ◽  
Sibel Aksoy ◽  
Mert Hakan Şimşek
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Laser Treatment ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Micropulse Laser ◽  
Vein Occlusion ◽  
Subthreshold Micropulse Laser ◽  
The Mean

Purpose: To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion. Methods: The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time. The patients received an injection or laser treatment at baseline and were, then, retreated as needed and were followed for 12 months. The mean best corrected visual acuity changes over the follow-up and the decrease in the mean central macular thickness were evaluated. Results: A total of 27 and 24 patients were assigned to intravitreal ranibizumab and subthreshold micropulse laser subgroups, respectively. The mean number of treatment was 3.81 of intravitreal ranibizumab group and 1.5 of subthreshold micropulse laser group (p < 0.05). The subgroups were similar with regard to the mean score of best corrected visual acuity at baseline, at 1, 6, and 12 months (p > 0.05). The decrease in the mean central macular thickness was significant in both intravitreal ranibizumab and subthreshold micropulse laser groups at 1, 6, and 12 months than that of values at baseline (p < 0.05). No new ocular or systemic adverse events were observed. Conclusion: Our study results showed that intravitreal ranibizumab or yellow subthreshold micropulse laser treatment for macular edema due to branch retinal vein occlusion was not found to be superior to each other for reducing macular thickness and increasing visual acuity for 1-year period. Based on these results, subthreshold micropulse laser may be a useful alternative approach in the treatment of macular edema secondary to branch retinal vein occlusion.

scholarly journals BEVACIZUMAB FOR RETINAL VEIN OCCLUSION

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Andrea Radotma Silitonga ◽  
Sindy Boru Sembiring ◽  
Christina Josephina Bangun ◽  
Heri Purwoko
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Real Life ◽  
Intravitreal Bevacizumab ◽  
Functional Improvement ◽  
Vein Occlusion ◽  
Before And After ◽  
Treatment Naïve ◽  
The Mean

Introduction: Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) caused sudden visual decrease that most often treatable. This paper aims to describe clinical characteristic and outcome using bevacizumab for macular edema caused by retinal vein occlusion in real-life practice. Methods: This retrospective study included 91 treatment-naïve eyes with macular edema due to CRVO (55 eyes) and BRVO (36 eyes), who were treated with intravitreal bevacizumab (IVB) in pro re nata (PRN) regimen. Best corrected visual acuity (BCVA) and central macular thickness (CMT) before and after treatment were evaluated. Result: The mean age of patients was 60.3 + 11.2 years for CRVO and 55.7 + 8.2 years for BRVO. The mean baseline BCVA in the CRVO group was 1.41 + 0.55 logMAR. There was statistically significant improvement in BCVA after intravitreal bevacizumab compared to baseline (p < 0.001) in CRVO and BRVO group. Twenty six (47.3%) eyes with CRVO had BCVA > 1.0 logMAR (Snellen 20/200) at the last follow-up. In the BRVO group, the mean baseline BCVA was 0.93 + 0.48 logMAR. At the end of the follow up, 19 eyes (52.8%) with BRVO had BCVA > 0.3 logMAR (Snellen 20/40). There was also statistically significant improvement in CMT between all time points and baseline (p < 0.001) in both groups. At the end of the follow up, 26 (47.3%) eyes with CRVO and 25 eyes (69.4%) in BRVO group presented resolution of macular edema (CMT < 300). Conclusion: Intravitreal bevacizumab resulted in significant anatomical and functional improvement in macular edema associated with CRVO and BRVO, although outcome in CRVO group was sub-optimal.

Neovaskulinės amžinės geltonosios dėmės degeneracijos gydymo ranibizumabu 24 mėnesių morfologiniai ir funkciniai pokyčiai

2015 ◽  
Vol 21 (3.2) ◽  
pp. 413-416
Author(s):  
Vilma Jūratė Balčiūnienė ◽  
Rosita Lažaunykaitė
Keyword(s):  
Visual Acuity ◽  
Macular Thickness ◽  
Age Related Macular Degeneration ◽  
Central Macular Thickness ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
Before And After ◽  
The Mean ◽  
The Difference ◽  
Best Corrected Visual Acuity

Key words: ranibizumab, age-related macular degeneration, central macular thickness. Research objective. To evaluate influence of treatment with vascular endothelial growth factor inhibitor, ranibizumab, for best corrected visual acuity and central macular thickness in patients with neovascular age-related macular degeneration. Materials and methods. In this retrospective study were included treatment – naive patients. Intravitreal injections were performed at Lithuanian University of Health Sciences Kaunas Clinics Eye clinic. In this study were analysed the 24-month morphological and functional outcomes of intravitreal ranibizumab injections. Best corrected visual acuity was meassured using the Snellen chart (Landolt’s rings C optotypes). Optical coherence tomography images were obtained using the spectral – domain OCT (NIDEK RS – 3000 Advance (NIDEK CO LTD, Japan). The central thickness measurements were obtained from macular thickness maps using the digital caliper tool. Results. In this study were included 88 patients. Best corrected visual acuity before treatment was 0.36 ± 0.22. The difference between visual acuity before and after first injection was 0.04 ± 0.22 (p = 0.03). Before fifth injection visual acuity was 0.41 ± 0.21, after – 0.46 ± 0.22 (p = 0.05). Central macular thickness before treatment was 297.81 ± 106.04 μm. The difference between central macular thickness before and after first injection was 85.21 ± 113.37 μm (p &lt; 0.001). Before second injection central macular thickness was 273.57 ± 87.49 μm, after – 234.51 ± 58.96 μm (p = 0.002). Before fourth injection central macular thickness was 237.20 ± 40.87 μm, after – 219.10 ± 42.26 μm (p = 0.04). The mean central macular thickness significantly decreased from 298.15 ± 104.78 to 229.08 ± 56.57 (p &lt; 0.001). In 24 month of treatment the average number of ranibizumab injections was 3.61 ± 1.55. Conclusions. Our study’s results showed that over 24 month best corrected visual acuity improvement was statistically significant after first and fifth injection. Baseline compared with last injection, there was not statistically significant difference. Central macular thickness improvement statistically significant was after first, second and fourth injection. There was statistically significant decreased baseline compared with the last injection. The mean number of ranibizumab injections was 3.61 ± 1.55 in 24 month.

scholarly journals Outcomes of Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

2020 ◽  
Vol 36 (3) ◽  
Author(s):  
Nasir Chaudhry ◽  
Sarmad Zahoor ◽  
Usama Iqbal ◽  
Muhammad Owais Sharif ◽  
Muhammad Sharjeel ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Macular Thickness ◽  
Female Ratio ◽  
Vein Occlusion ◽  
Vitreoretinal Traction ◽  
Quasi Experimental ◽  
Study Institute

Purpose: To determine the functional and anatomical outcome of intravitreal Bevacizumab in patients withmacular edema secondary to branch retinal vein occlusion.Study Design: Quasi Experimental study.Place and Duration of Study: Institute of Ophthalmology, Mayo hospital, Lahore, from February 2016 to December 2018.Material and Methods: Forty eyes of 40 patients with macular edema on OCT secondary to BRVO were included in the study. All the patients suffering from other types of macular edemacaused by diabetes, epi-retinal membrane (ERM), surgery involving posterior segment, vitreoretinal traction andhistory of intravitreal VEGF or steroids were excluded from the study. Intravitreal Bevacizumab was given whenmacular thickness was > 300 μm or Visual acuity was < 6/12. Follow-up was at 1st, 3rd, 6th and 12th month.Results: The mean age of the patients was 52.12 ± 5.63 years. Male to female ratio was 1.5:1. Infero-temporalvenous arcade was the most common site of BRVO (55%) followed by supero-temporal (35%) and macularBRVO (10%). Baseline visual acuity was 6/12 or better in 17.5% of the patients at presentation. This proportionincreased to 27.5%, 40%, 52.5% and 67.5% at 1, 3, 6 and 12 months respectively. Macular thickness measuredat presentation was 540 ± 120 μm. Macular thickness gradually reduced on follow-up. At one month meanmacular thickness was 430 ± 90 μm. It was less than 300 μm after 6 months.Conclusion: Intravitreal bevacizumab results in improved functional and anatomical outcomes in cases ofmacular edema secondary to BRVO.

scholarly journals Karakteristik Ketebalan Makula Sentral Sebelum dan Sesudah Injeksi IntravitrealBevacizumab di RSKM Padang Eye Center Periode Januari 2018 – Januari 2019

2020 ◽  
Vol 2 (2) ◽  
pp. 01-07
Author(s):  
Haves Ashan
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Fluid Accumulation ◽  
Blood Retinal Barrier ◽  
Vein Occlusion ◽  
Before And After ◽  
Center Hospital ◽  
Age Range

Macular edema is a common cause of vision disturbing. Fluid accumulation in the retina and increased thickness of the retina cause damage to the blood retinal barrier. Intravitreal anti-VEGF (bevacizumab) injection aims to reduce VEGF activity, where retinal vein occlusion (RVO) induces an increase in VEGF levels which causes an increase in vascular permeability and results in macular edema. The aim of this study was to determine the central macular thickness before and after intravitreal injection of bevacizumab in patients with central retinal vein occlusion and branch retinal vein occlusion through observing the results of OCT (Optical Coherence Tomography) examination. This research is a retrospective descriptive study based on the results of medical records tracing of 8 RVO patients in the Padang Eye Center Hospital for the period January 2018 to January 2019. The study was conducted in March to April 2020. The study subjects consisted of 8 people (8 eyes) consisting of 2 men (25.0%) and 6 women (75.0%). The age range ranges from 41-80 years. The thickness of the central macula at the start was found to be majority > 300 μm, as many as 7 people (87.5%), while ≤ 300 μm was 1 person (12.5%). One month after injection found the majority of central macular thickness ≤ 300 μm by 5 people (62.5%), while> 300 μm is as many as 3 people (37.5%). All patients experienced a decrease in central macular thickness in 8 subjects (100%).

scholarly journals Effect of Intravitreal Bevacizumab in Macular Edema Caused by Branch Retinal Vein Occlusion

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Imran Ahmad, Mubashir Rehman, Mir Ali Shah, Irfan Aslam Khattak
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Interrupted Time Series ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Vein Occlusion ◽  
Department Of Ophthalmology

Purpose: To evaluate the effect of intra-vitreal bevacizumab in macular edema caused by branch retinal vein occlusion. Study Design: Interrupted time series study. Place and Duration of Study: Department of Ophthalmology Hayatabad Medical Complex, Peshawar and department of Ophthalmology Lady Reading Hospital Peshawar from 1st July 2016 to 31st December 2016. Material and Methods: There were 60 patients included in the study. All patients with macular edema due to BRVO visible clinically and evident on SD-OCT and visual acuity of less than 6/9 were included in the study. Patients who used other intra-vitreal drug for macular edema, those with surgery in the same eye and those with macular laser for macular edema were excluded from the study. All patients were given intra-vitreal 0.05 ml bevacizumab injection every month for 6 months. After 6 months OCT was repeated. At each monthly visit VA was measured and fundoscopy was done. Follow up of all patients was at six months. Results: Our study included 60 patients with mean age of 54.42 ± 9.19 years. The mean baseline central macular thickness was 427.06 µ with SD ± 63.54 µ. After 6 months significant improvement in visual acuity was documented. Also marked reduction in central macular thickness was noted after six months with mean of 327.44 µ with SD ± 55.55 µ. Conclusion: Intra-vitreal bevacizumab is an effective treatment for macular edema caused by BRVO in terms of both anatomic and visual improvement. Key words: Branch retinal vein occlusion, bevacizumab, macular edema.

scholarly journals Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

2020 ◽  
Vol 36 (3) ◽  
Author(s):  
Hussain Ahmad Khaqan ◽  
Usman Imtiaz ◽  
Hasnain Muhammad Buksh ◽  
Hafiz Ateeq Ur Rehman ◽  
Raheela Naz
Keyword(s):  
Macular Degeneration ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Macular Thickness ◽  
Age Related Macular Degeneration ◽  
Central Macular Thickness ◽  
Safety And Efficacy ◽  
Vein Occlusion ◽  
Age Related ◽  
The Mean

Purpose:  To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for the management of edema caused by different retinal pathologies. Study Design:  Comparative interventional study. Place and Duration of Study:  Lahore General Hospital, Lahore, from July 2018 to June 2019. Material and Methods:  Patients with resistant, center involving macular edema due to diabetes, retinal vein occlusion and age related macular degeneration were recruited. Complete ocular examination was performed. All the patients were randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) and IVB (intravitreal bevacizumab). Each eye underwent intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab. Outcome was measured in terms of variation in central macular thickness (CMT) and also best corrected visual acuity (BCVA) at 3 months. Results:  Total of 156 eyes of 136 patients completed whole duration of study and were included in the results. The mean baseline CMT was 510 μm (± 94 μm) in the IVB group and 493μm (±102 μm) in the IVZ group (P = 0.94). The mean baseline BCVA (log MAR) was 0.78 (Snellen's equivalent 6/36) in the IVZ and 0.70 (Snellen's equivalent 6/30) in the IVB group (P = 0.78). Central macular thickness was significantly reduced at 1st, 2nd and 3rd month in the IVZ group and IVB group (P < 0.001). Conclusion:  Intravitreal Ziv-Aflibercept is safe and more effective than Bevacizumab for the treatment of edema caused by diabetes mellitus, retinal vein occlusion and wet age related macular degeneration.

scholarly journals Evaluation of Intravitreal Bevacizumab injection in treatment of diabetic macular edema in eyes with Good visual acuity

2021 ◽  
Author(s):  
seyed aliasghar mosavi
Keyword(s):  
Visual Acuity ◽  
Treatment Group ◽  
Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Macular Thickness ◽  
Control Group ◽  
The Mean ◽  
The Difference ◽  
Good Vision

Abstract Aims To determine the effect of intravitreous Bevacizumab injection on reducing diabetic macular edema in patients with good vision. Method : This clinical trial was conducted on diabetic patients with centrally involved macular edema and good vision over a period of one and a half year. 22 eyes of 12 patients with a visual acuity of Snellen equivalent of 20/25 or better in the non-proliferative stage with the central macular thickness of more than 300 microns in optical coherence tomography (OCT) were evaluated. In the injection group 1.25 Mg of bevacizumab (Avastin) was injected intravitreally and the control group was followed up. Macular thickness and visual acuity were measured in two groups at first and sixth months after injection. Results Intravitreal bevacizumab was injected in 12 eyes (55%) and 10 patients were followed-up as a control group (45%). The mean central macular thickness was 319 µm at first visit and 301 µm at month six in the treatment group and in the control group it was 318 µm and 328 µm respectively. The mean macular thickness of the treatment group was significantly decreased (p = 0.031), but the difference was not statistically significant between two groups (p = 0.581). The mean visual acuity in the treatment group was 0.045 Log MAR at first visit and 0.033 Log MAR at the sixth month follow up, these values in the control group were 0.1 Log MAR and 0.045 Log MAR respectively and did not differ statistically between the two groups (p = 0.373) Conclusion Although the mean macular thickness was reduced in the treatment group with visual acuity of 20/25 or better but the difference was not significant during follow-up at least in a short period. Therefore, the role of underlying factors other than VEGF alone can be notable in the pathogenesis of the disease.

Change in Visual Acuity in Relation to Central Macular Thickness after Intravitreal Bevacizumab in Diabetic Macular Edema

2020 ◽  
Vol 36 (3) ◽  
Author(s):  
Muhammad Ali Haider ◽  
Uzma Sattar ◽  
Syeda Rushda Zaidi
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Macular Thickness ◽  
Rank Test ◽  
P Value ◽  
Central Macular Thickness ◽  
Anti Vegf ◽  
Quasi Experimental

Purpose: To evaluate the change in visual acuity in relation to decrease in central macular thickness,after a single dose of intravitreal Bevacizumab injection.Study Design: Quasi experimental study.Place and Duration of Study: Punjab Rangers Teaching Hospital, Lahore, from January 2019 to June 2019.Material and Methods: 70 eyes with diabetic macular edema were included in the study. Patients having high refractive errors (spherical equivalent of > ± 7.5D) and visual acuity worse than +1.2 or better than +0.2 on log MAR were excluded. Central macular edema was measured in μm on OCT and visual acuity was documentedusing Log MAR chart. These values were documented before and at 01 month after injection with intravitrealBevacizumab. Wilcoxon Signed rank test was used to evaluate the difference in VA beforeand after the anti-VEGF injection. Difference in visual acuity and macular edema (central) was observed,analyzed and represented in p value. P value was considered statistically significant if it was less than 0.01%.Results: Mean age of patients was 52.61 ± 1.3. Vision improved from 0.90 ± 0.02 to 0.84 ± 0.02 on log MARchart. The change was statistically significant with p value < 0.001. Central macular thickness reduced from 328 ±14 to 283 ± 10.6 μm on OCT after intravitreal anti-VEGF, with significant p value < 0.001.Conclusion: A 45 μm reduction in central macular thickness was associated with 0.1 Log MAR unit improvementin visual acuity after intravitreal Bevacizumab in diabetic macular edema.

Sign in / Sign up

Export Citation Format

Share Document